TrialInvestigational new drugs2022

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.

Lakshmi Rajdev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.